Bayer: Hemophilia A trials

The registry lists 57 Hemophilia A studies with Bayer as lead sponsor. 3 are open to participants now and 14 have results posted.

Phase 1 11Phase 2 5Phase 3 9Phase 4 8No phase 27(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Post Approval Phase 4 Study to Learn More About How Safe Octocog Alfa is, and How Well it Works in Patients With Severe Hemophilia A in IndiaNot yet recruitingNCT07446010
• An Observational Study to Learn More About How Well Damoctocog Alfa Pegol Works in Children With Hemophilia ARecruitingNCT07088458
• A Study to Learn More About the Safety of Damoctocog-alfa-pegol When Used in Routine Medical Care in Korean Participants With Hemophilia ARecruitingNCT06222697
• A Study to Learn How Safe the Study Treatment BAY94-9027 is and How it Affects the Body in Previously Treated Children Aged 7 to Less Than 12 Years With Severe Hemophilia A, a Genetic Bleeding Disorder That is Caused by the Lack of a Protein Called Clotting Factor 8 (FVIII) in the BloodCompletedNCT05147662Phase 3Results posted
• Prophylaxis Regimen for Hemophilia A PatientsCompletedNCT05036278Phase 4Results posted
• A Post Approval Commitment Study to Gain More Information on How Safe and Effective KOVALTRY is in Chinese Children, Adolescents /Adults With Severe Hemophilia ACompletedNCT04565236Phase 4Results posted
• Study to Gain More Information on How Safe and Effective Jivi Works in Patients With Severe Hemophilia A (Post-marketing Investigation)CompletedNCT04085458Phase 4Results posted
• Multiple Escalating Dose Study of BAY1093884 in Adults With Hemophilia A or B With or Without InhibitorsTerminatedNCT03597022Phase 2Results posted
• Prophylaxis Versus on Demand Treatment for Children With Hemophilia ACompletedNCT01810666Phase 4Results posted
• A Trial Investigating Safety and Efficacy of Treatment With BAY94-9027 in Severe Hemophilia ACompletedNCT01580293Phase 2/3Results posted
• BAY81-8973 Pediatric Safety and Efficacy TrialCompletedNCT01311648Phase 3Results posted
• A Trial to Compare Prophylaxis Therapy to On-demand Therapy With a New Full Length Recombinant FVIII in Patients With Severe Hemophilia ACompletedNCT01233258Phase 3Results posted
• Trial to Evaluate the Efficacy and Safety of a New Full Length Recombinant Human FVIII for Hemophilia ACompletedNCT01029340Phase 3Results posted
• Russian Kogenate Pediatric StudyCompletedNCT00632814Phase 4Results posted
• BAY79-4980 Compared to rFVIII-FS in Previously Treated Patients With Severe Hemophilia ATerminatedNCT00623727Phase 2Results posted
• Trial to Evaluate the Effect of Secondary Prophylaxis With rFVIII Therapy in Severe Hemophilia A Adult and/or Adolescent Subjects Compared to That of Episodic TreatmentCompletedNCT00623480Phase 3Results posted
• BAY14-2222 Prophylaxis and Joint Function Improvement (Adults)CompletedNCT00586521Phase 4Results posted
• An Observational Study Called JOIHA to Learn More About How Well the Treatment With Jivi Works to Prevent Problems With Joints in Adults With Hemophilia A.Active, not recruitingNCT05643560
• A Study to Learn More About Treatment With Damoctocog Alfa Pegol, How it is Used in Every Day Practice ("Real-World"), and How Satisfied People Who Receive Damoctocog Alfa Pegol Are in United States (US) Hemophilia Treatment CentersTerminatedNCT05395858
• Study to Learn More About the Safety of Drug Jivi Over a Long Period of Time in Previously Treated Patients With Hemophilia A (Bleeding Disorder Resulting From a Lack of FVIII) Who Are Receiving Jivi Regularly at Their Treating Doctors to Prevent BleedingActive, not recruitingNCT04461639
• Study to Learn More About the Physical Activity Level of Patients Suffering From Hemophilia A Treated With Damoctocog Alfa Pegol (LIFE ACTIVE Study)CompletedNCT04091386
• Study to Compare How the Body Distributes and Excretes the Drugs Jivi (BAY 94-9027) and Adynovi in Patients With Severe Hemophilia A (Bleeding Disorder Resulting From a Lack of Blood Clotting Factor VIII)CompletedNCT04015492Phase 1
• Study to Test the Safety of an Investigational Drug Given Repeatedly to Adult Men With Severe HemophiliaWithdrawnNCT03996486Phase 1
• Evaluating Effectiveness and Long Term Safety of Damoctocog Alfa Pegol in Patients, Who Have Been Diagnosed With Hemophilia AActive, not recruitingNCT03932201
• Assessing Physician and Hemophilia A Patient Reasons and Expectations for Switching Treatment to Kovaltry & Jivi: A Nested Study Within an Existing RegistryTerminatedNCT03603275
• Study to Test the Safety and How Well Patients With Severe Hemophilia A Respond to Treatment With BAY 2599023 (DTX 201), a Drug Therapy That Delivers a Healthy Version of the Defective Factor VIII Gene Into the Nucleus of Liver Cells Using an Altered, Non-infectious Virus (AAV) as a "Shuttle"CompletedNCT03588299Phase 1/2
• A Study to Assess Pharmacokinetics and Pharmacodynamics Following Administration of BAY1093884 in Patients With Severe HemophiliaCompletedNCT03481946Phase 1
• Evaluation of Patient and Physician Reported Reasons for Switching Factor VIII Replacement TherapiesCompletedNCT03405337
• BAY94-9027 PK Study Comparing to Another Long Acting ProductCompletedNCT03364998Phase 1
• Exit Interviews to Assess Impact of Infusion Frequency in Hemophilia ACompletedNCT02971930
• Drug Use Investigation of Kovaltry in Hemophilia A PatientsCompletedNCT02941783
• Study Evaluating "Real World" Treatment Pattern in Previously Treated Hemophilia A Patients Receiving KOVALTRY (Octocog Alfa) for Routine ProphylaxisCompletedNCT02830477
• Extension at 10 Years of the: "Observational Study Evaluating Efficacy and Costs of Secondary Prophylaxis vs On-demand Therapy With Kogenate Bayer in Patients With Severe Haemophilia A."CompletedNCT02581969
• A Single Escalating Dose and Multiple Dose Study of BAY 1093884 in Subjects With Severe Hemophilia Types A or B, With or Without InhibitorsCompletedNCT02571569Phase 1
• Single Dose Study in Subjects With Severe Hemophilia A Comparing Pharmacokinetic Parameters for BAY81-8973 and AdvateCompletedNCT02483208Phase 1
• Patient Functioning and Well-being, Economic, and Clinical Impact of Hemophilia A and Its TreatmentCompletedNCT02396862
• 2-cohort Study of Adult Patients With Severe Hemophilia A in GreeceCompletedNCT02319070
• Colorado Adult Joint Assessment Scale (CAJAS) ValidationCompletedNCT02284789Not applicable
• Retrospective Study in Chinese Pediatric Hemophilia A Patients With rFⅧ Contained Regular ProphylaxisCompletedNCT02263066
• Study of FVIIa Variant BAY86-6150 (B0189) in Subjects With Moderate or Severe Hemophilia Types A or B With or Without InhibitorsCompletedNCT01921855Phase 1
• Comparison of Efficacy, Safety and Costs of Recombinant FVIII Products Between On-demand and Secondary Prophylaxis Groups in Haemophilia A PatientsCompletedNCT01817868
• Safety and Efficacy of BAY94-9027 in Previously Treated Male Children With Haemophilia ACompletedNCT01775618Phase 3
• Comparative Pharmacokinetic Study of Two Different Strengths of BAY14-2222CompletedNCT01653639Phase 1
• A Phase 2/ 3 Trial to Evaluate the Efficacy and Safety of BAY86-6150CompletedNCT01625390Phase 2/3
• Validation Study of a cOmputer Pharmacokinetic Tool to assIst in the Follow up Care of haeMophilia A PatientsCompletedNCT01436825
• Kogenate FS Regulatory Post-Marketing SurveillanceCompletedNCT01386268
• Trial to Evaluate the Pharmacokinetics and Safety Profile of BAY94-9027 Following Single and Multiple Dose AdministrationCompletedNCT01184820Phase 1
• Prophylaxis Versus On-demand Therapy Through Economic ReportCompletedNCT01159587
• Effekt-2 - Efficacy and Safety of Long-term Treatment With KOGENATE® FS in Latin AmericaCompletedNCT00969319
• EffeKt Taiwan- Efficacy and Safety of Long-term Treatment With KOGENATE® FS in TaiwanCompletedNCT00932555
• Joint Status in Subjects With Severe Hemophilia A in Relation to Different Treatment RegimensCompletedNCT00927667Phase 4
• Non-interventional Observation of Practical Implementation, Efficacy and Safety of Continuous Infusion With KOGENATE Bayer in SurgeryCompletedNCT00922597
• EFFEKT - Efficacy and Safety of Long-term Treatment With KOGENATE Bayer/FSCompletedNCT00874926
• International PMS Study - KOGENATE BayerCompletedNCT00864552
• Pharmacokinetics and Safety of a Single Intravenous Infusion of BAY 79-4980CompletedNCT00629837Phase 1
• Assessment of the Risk of Inhibitor Formation in Previously Treated Patients With Severe Hemophilia ATerminatedNCT00621673Phase 4
• BAY14-2222 Continuous Infusion in SurgeriesCompletedNCT00606060Phase 3